Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion–Related Events with Brolucizumab

Monés, Jordi; Srivastava, Sunil; J. Jaffe, Glenn; Tadayoni, Ramin; A. Albini, Thomas; K. Kaiser, Peter; G. Holz, Frank; Korobelnik, Jean‐François; K. Kim, Ivana; Pruente, Christian; G. Murray, Timothy; S. Heier, Jeffrey

doi:10.1016/j.ophtha.2020.11.011

Public

Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion–Related Events with Brolucizumab

Published in Ophthalmology • Nov 15, 2020

Authors:

Jordi Monés

Sunil Srivastava

Glenn J. Jaffe

Abstract

PURPOSE: An independent Safety Review Committee (SRC), supported by Novartis Pharma AG, analyzed investigator-reported cases of intraocular inflammation (IOI), endophthalmitis, and retinal arterial occlusion in the phase 3 HAWK and HARRIER trials of brolucizumab versus aflibercept in neovascular age...

Subject

Medicine

Retinal vasculitis

Aflibercept

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!